Upadacitinib Approved for Moderate to Severe Rheumatoid Arthritis - Rheumatology Advisor

Upadacitinib Approved for Moderate to Severe Rheumatoid Arthritis  Rheumatology Advisor

The FDA has approved Rinvoq (upadacitinib), a Janus kinase (JAK) inhibitor, for the treatment of adults with moderately to severely active rheumatoid arthritis ...



Comments

Popular posts from this blog

Fibromyalgia — Latest Stories — Pain News Network

Chronic Lyme arthritis: A mystery solved?

Epstein-Barr virus and autoimmune diseases